Function Health, a health management platform, has partnered with healthcare company GRAIL to offer multi-cancer early detection test in the US.
The collaboration expands access to GRAIL’s Galleri test, a multi-cancer early detection test, extending the reach of advanced cancer screening to transform cancer care.
Function Health said the Galleri test is a first-of-its-kind, clinically validated multi-cancer early detection (MCED) test.
GRAIL, a spin-off from Illumina, has designed the test to screen multiple cancers with a simple blood draw.
Over 100,000 eligible members of Function Health will now have access to this test. This adds to Function Health’s extensive list of 100+ lab tests.
According to Function Health, the Galleri test detects a fingerprint of many deadly cancers before symptoms appear. It screens for cancers that currently lack recommended screening tests, such as oesophageal, pancreatic, ovarian, and liver cancers.
The test is recommended for adults at elevated cancer risk, including those aged 50 and older, and is available by prescription only.
Function Health co-founder and chief medical officer Mark Hyman said: “Offering the Galleri test in collaboration with GRAIL is essential to ensuring that multi-cancer early detection becomes a routine part of people’s annual health checkups in addition to other recommended screenings, giving us a better chance to screen for cancer before it becomes symptomatic when there may be more treatment options.”
Function Health offers members access to over 100 lab tests, covering areas like heart health, hormones, thyroid, nutrients, toxins, and autoimmune markers.
With insights from clinicians and personalised lifestyle recommendations, the health management platform helps members gain essential information to better manage their health and detect potential issues early.
By providing access to GRAIL’s Galleri test, Function Health has already helped many members identify cancers at an early, presymptomatic stage, giving them an option to take proactive action and access vital resources throughout their cancer journey.
GRAIL president Josh Ofman said: “GRAIL is using the power of state-of-the-art computer and data science as well as data from one of the largest clinical programs in genomic medicine to date to help solve one of medicine’s greatest challenges.”
The announcement follows Function Health’s recent nationwide expansion, including launches in New York and New Jersey. It also comes after a new partnership with Thrive Global, introducing a precision health coaching program for employees.
